Rouge Therapeutics announced USD 58 million in Series A funding on Tuesday 6 October 2026. BioGeneration Ventures, Angelini Ventures with the EIB Aurea facility, and Kurma Partners are named co-leads. The Netherlands company, also known as RougeTx, is a Leiden University Medical Center spinout developing an oral treatment for hereditary hemorrhagic telangiectasia. The financing supports its move toward clinical studies. Its investment story combines university-origin research with a defined rare-disease programme and specialist capital. Rouge's work remains a drug-development effort, with the round backing the research and preparation needed to advance the proposed treatment through the next stages of development.
Rouge Therapeutics raises USD 58m Series A
Specialist investors back an oral treatment for a hereditary bleeding disorder

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


